Schwartzberg LS - Search Results

1

Clinical roundtable monograph. Treatment of chemotherapy-induced nausea and vomiting: a post-MASCC 2010 discussion.

Kris MG, Urba SG, Schwartzberg LS. Kris MG, et al. Among authors: schwartzberg ls. Clin Adv Hematol Oncol. 2011 Jan;9(1):suppl 1-15. Clin Adv Hematol Oncol. 2011. PMID: 21370520

2

Acute chest pain syndrome during bleomycin infusions.

White DA, Schwartzberg LS, Kris MG, Bosl GJ. White DA, et al. Among authors: schwartzberg ls. Cancer. 1987 May 1;59(9):1582-5. doi: 10.1002/1097-0142(19870501)59:9<1582::aid-cncr2820590909>3.0.co;2-#. Cancer. 1987. PMID: 2435402

3

Chemotherapy-induced nausea and vomiting: state of the art in 2006.

Schwartzberg L. Schwartzberg L. J Support Oncol. 2006 Feb;4(2 Suppl 1):3-8. J Support Oncol. 2006. PMID: 16499138 Review.

4

Chemotherapy-induced nausea and vomiting: clinician and patient perspectives.

Schwartzberg LS. Schwartzberg LS. J Support Oncol. 2007 Feb;5(2 Suppl 1):5-12. J Support Oncol. 2007. PMID: 17366928 Review.

5

Chemotherapy-induced nausea and vomiting: which antiemetic for which therapy?

Schwartzberg LS. Schwartzberg LS. Oncology (Williston Park). 2007 Jul;21(8):946-53; discussion 954, 959, 962 passim. Oncology (Williston Park). 2007. PMID: 17715696 Free article. Review.

6

Recent Advances in the Management of Chemotherapy-induced Nausea and Vomiting: A Case Study Compendium.

Morrow GR, Hesketh PJ, Schwartzberg LS, Ettinger DS. Morrow GR, et al. Among authors: schwartzberg ls. Clin Adv Hematol Oncol. 2010 May;8(5 Suppl 9):1-16. Clin Adv Hematol Oncol. 2010. PMID: 20956915 No abstract available.

7

Likelihood of a subsequent chemotherapy-induced nausea and vomiting (CINV) event in patients receiving low, moderately or highly emetogenic chemotherapy (LEC/MEC/HEC).

Schwartzberg L, Szabo S, Gilmore J, Haislip S, Jackson J, Jain G, Balu S, Buchner D. Schwartzberg L, et al. Curr Med Res Opin. 2011 Apr;27(4):837-45. doi: 10.1185/03007995.2011.556603. Epub 2011 Feb 10. Curr Med Res Opin. 2011. PMID: 21309647

8

Chemotherapy-induced nausea and vomiting and antiemetic prophylaxis with palonosetron versus other 5-HT3 receptor antagonists in patients with cancer treated with low emetogenic chemotherapy in a hospital outpatient setting in the United States.

Schwartzberg L, Morrow G, Balu S, Craver C, Gayle J, Cox D. Schwartzberg L, et al. Curr Med Res Opin. 2011 Aug;27(8):1613-22. doi: 10.1185/03007995.2011.596201. Epub 2011 Jun 22. Curr Med Res Opin. 2011. PMID: 21696263 Clinical Trial.

9

Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.

Schwartzberg L, Jackson J, Jain G, Balu S, Buchner D. Schwartzberg L, et al. Expert Rev Pharmacoecon Outcomes Res. 2011 Aug;11(4):481-8. doi: 10.1586/erp.11.47. Epub 2011 Jun 28. Expert Rev Pharmacoecon Outcomes Res. 2011. PMID: 21711119

10

The role of second-generation 5-HT3 receptor antagonists in managing chemotherapy-induced nausea and vomiting in hematological malignancies.

Schwartzberg LS, Jacobs P, Matsouka P, Azevedo W, Pinto A. Schwartzberg LS, et al. Crit Rev Oncol Hematol. 2012 Jul;83(1):59-70. doi: 10.1016/j.critrevonc.2011.09.005. Epub 2012 Feb 7. Crit Rev Oncol Hematol. 2012. PMID: 22321726 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

302 results

Search Page

Filters